DiagnoCure has also continued to develop robust molecular tests that address unmet clinical needs. This effort contributes management credibility to discussions with potential partners.
Nominations by DiagnoCure in the best interest of shareholders
DiagnoCure's nominees, who are all current directors of the Corporation, control, directly or indirectly, 2,135,846 shares of the Corporation representing approximately 5.0% of all issued and outstanding shares. They present themselves as a team. Consequently, it is likely that individual board members, including Dr.
, will not choose to continue in their roles as directors unless the entire team is re-elected.
"With a recently renewed Board, bringing together diversified outstanding talents and wide‐ranging experience, DiagnoCure is advancing a plan to increase shareholder value. We believe that untimely changes to DiagnoCure's board would send a negative message to our potential partners and to the financial markets," indicated Dr.
, Chairman of the Board, and President and Chief Medical Officer of the Corporation.
Consequently, DiagnoCure's management and Board of directors maintain their recommendation to vote in favor of their candidates, as indicated in the management proxy circular dated
March 11, 2013
About DiagnoCure's nominees
, 62, from Québec,
, is co-founder of the Corporation and Chairman of the Board of directors of DiagnoCure since
and President of the Corporation since
. He graduated from Medical School at Université
in 1976 and is member of the Royal College of Physicians and Surgeons of
since 1981. He has been professor of surgery/urology at Université
since 1992. Dr. Fradet studied at the Memorial Sloan-Kettering Cancer Center in
from 1981 to 1983, where he sub-specialized in urologic oncology. He is a member of several national and international associations including the American Association of Genitourinary Surgeons limited to 75 active members in
among the leaders of urology. Dr. Fradet received numerous honours during his career including the Lifetime career achievement award from the Canadian Urology Association in 2012 and the Queen
Elizabeth Diamond Jubilee Medal
from Canadian Medical Association in 2013.
, 62, from Montréal,
, holds a Ph.D. in physiology from Université
and pursued postdoctoral studies at the
. She has close to 30 years experience in research and science management. From 1977 to 1985, she focused her efforts on prostate and breast cancer at the
hospitalier de l'Université
. From 1985 to 2001, she took over scientific positions of increasing responsibilities, notably as Vice President, Scientific Affairs at Hoechst Marion Roussel Canada, and Vice President, Therapeutic Product Development at Biochem Pharma. She was later Vice President, Business Development of Genome Québec (2001-2002), Vice Principal Research at
(2002-2004) and Vice President, Product Development at Topigen Pharmaceuticals, Inc. (2004-2006). From
, she was Vice President, Product Development at ViroChem Pharma, Inc. This company was acquired in
by Vertex Pharmaceuticals, and Dr. Proulx was named Vice President, Research and Development of the Canadian arm. In 2011, she became Vice-President and Site Head until
. Dr. Proulx has been a member of several Boards of directors over her career, and is currently director of the Canada Foundation for Innovation, of Univalor inc., of the Research Institute of the
Health Center (RIMUHC) and of BioQuébec. She is certified ICD.D by the Institute of Corporate Directors.
, 57, from Québec,
, has been President and Chief Executive Officer of Medicago Inc., a clinical-stage biopharmaceutical company, since
. He has thirty years of experience in the pharmaceutical industry, and was named CEO of the Year by the Vaccine Industry Excellence awards at the World Vaccine Congress in
. Before joining Medicago, Mr. Sheldon was Vice-President, Sales and Marketing of Shire Biologics, where he was responsible for international expansion with European, American and Asian private partnership agreements and was also responsible for distribution, customer service, maintenance and engineering at the Shire facility. From 1998 to 2000, he was Senior Manager of Commercial Operations where he successfully managed the approval of a bladder cancer therapeutic vaccine by the FDA. In 1997 and 1998, he was Marketing Manager for Merial Canada Inc. From 1992 to 1997, he was Director of Canadian Operations with Rhône Mérieux. From 1988 to 1992, he was National Sales Manager for SmithKline Beecham. Mr. Sheldon has a Bachelor's degree in agricultural sciences from Université
, Québec City and a Bachelor's of science degree with honors in biological sciences from the University of
, 55, from
, is President & CEO and director of Gestion Univalor, L.P., a limited partnership responsible for the commercialization and transfer of technologies and innovations created at Université de Montréal, its affiliated schools Polytechnique Montréal (engineering) and HEC Montréal (business), and its hospitals and health research centres. Dr. Simoneau is a corporate director with a comprehensive experience in venture capital and private equity. Prior to joining Univalor, he was Executive Vice President, Investments of the Business Development Bank of
(BDC). In that capacity, he was responsible for the venture capital and subordinate financing portfolios. Prior to that, he was President and CEO of Hydro-Québec CapiTech Inc., Senior Vice-President of the
Fonds de solidarité FTQ
and CEO of
Société Innovatech du sud du Québec
. He also held executive positions at Advanced Scientific Computing and Alcan. Dr. Simoneau is a director of Transat Inc. A.T., of Azimut Exploration, and of Sustainable Development Technology Canada. He serves on the scientific committee of the
Centre québécois de recherche et de développement
and on the University of Montréal's Faculty of Medicine's advisory committee. Dr. Simoneau was a member of the
Conseil de la science et de la technologie du
from 2004 to 2011, and was also director of three other public companies and 14 private companies between 1995 and now.
is a mechanical engineer and holds a M.Sc. from Université
and a Ph.D. from Queen's University. He is a member of the
Ordre des ingénieurs
of Professional Engineers Ontario and he is certified ICD.D by the Institute of Corporate Directors.
Vincent R. Zurawski
, 66, from
West Chester, Pennsylvania
, earned his Ph.D. from
in 1973 and completed post-doctoral training at the
General Hospital and
Harvard Medical School
. Dr. Zurawski was a pioneer in the biotechnology industry. In 1979, he was one of the founders of Centocor, Inc., where he played a major role in developing and implementing the successful business strategy of the company and the development of all its cancer diagnostic products. In 1992, Dr. Zurawski was founder, President and Chief Executive Officer of Apollon, Inc. and during his six-year tenure at Apollon, he built an operation from the ground up that established itself as a leader in the development of DNA-based vaccines with five Apollon-manufactured products in clinical trials. In 1998, the company was sold to American Home Products (Wyeth Pharmaceuticals), which has since been acquired by Pfizer & Company. Pfizer continues to develop the Apollon DNA-based vaccines. From 1998 to 2000, Dr. Zurawski served as Director for Research Business Development for the
University of Pennsylvania
, Health System and School of Medicine and in 2000 he was named Chief Executive Officer of Compugen, Inc., the wholly-owned U.S. subsidiary of Compugen, Ltd., a company specializing in the commercialization of bioinformatics software systems. Since leaving Compugen, Inc., Dr. Zurawski has been engaged in a number of start-up biotechnology companies. Following a 3-year tenure as a board member of Hepregen Corporation, he was recently named President and Chief Executive Officer of Hepregen, a leader in the development of micro-liver products. He is also Founding President and Chief Scientific Officer of Varinel, Inc., a pharmaceutical company that specializes in the development of drugs for treatment of diseases of the central nervous system.
None of the proposed directors is, as of the date of this press release or has been within 10 years before
March 11, 2013
, which is the date of the management proxy circular, a director or an officer of a company that while that person was acting in that capacity or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.
In addition, none of the proposed directors has, within the 10 years before the date of the management proxy circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of such proposed director.